**6-Alpha Naloxol**

**Cat. No.:** HY-12799  
**CAS No.:** 20410-95-1  
**Molecular Formula:** C₁₉H₂₃NO₄  
**Molecular Weight:** 329.39  
**Target:** Opioid Receptor  
**Pathway:** GPCR/G Protein; Neuronal Signaling  
**Storage:** Please store the product under the recommended conditions in the Certificate of Analysis.  
**Solubility:** 10 mM in DMSO  
* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

### PREPARING STOCK SOLUTIONS

<table>
<thead>
<tr>
<th>Concentration</th>
<th>Volume</th>
<th>Mass</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mg</td>
<td>3.0359 mL</td>
<td>15.1796 mL</td>
</tr>
<tr>
<td>5 mg</td>
<td>0.6072 mL</td>
<td>3.0359 mL</td>
</tr>
<tr>
<td>10 mg</td>
<td>0.3036 mL</td>
<td>1.5180 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

**Description**  
6-Alpha Naloxol (Alpha-Naloxol) is an opioid antagonist closely related to naloxone; a human metabolite of naloxone. IC₅₀ value: Target: opioid antagonist  
When responding over the entire 30 min operant session was examined, naloxone was only 5-fold more potent than 6-alpha-naloxol in suppressing operant responding under Morphine Naïve conditions, but this increased to a 65-fold potency difference after Single or Repeat Morphine pretreatment. Examination of the relative potency of these antagonists in the Early Phase of operant testing (5-15 min post-antagonist) revealed an even greater 100-fold potency difference between naloxone and 6-alpha-naloxol, but in the Late Phase of testing (25-35 min post-antagonist), this had declined to a 9-fold potency difference, comparable to the relative potency of naloxone to 6-alpha-naloxol under Morphine-Naïve conditions.

### REFERENCES
